Key Facts
In a July 15, 2026 letter, the Agency for HealthcareResearch and Quality (AHRQ), broadly notified researchers it was halting at least 104 active grants, many aimed at improving patient safety [1]. Congress appropriated $345 million for AHRQ in fiscal 2026, but the agency had spent less than $15 million on grants and had not issued a single new award in over a year at the time of the letter [1]. This follows anear-total staffing collapse: roughly 75% of AHRQ's workforce is reduced since early 2025, leaving 74 employees where there were once close to 300 [1]. For sponsors, health systems, and sites that rely on AHRQ-funded safety and quality infrastructure, this is a live funding and operational risk, and litigation and congressional pushback are already underway.
$345M Appropriated for FY2026
<$15M Actual spend on grants
75% Staff reduction
78+ Grants confirmed halted, $200M value
Sources: KFF Health News [1]; STAT News, via CASRAI [2]
What the July 15 letter said
AHRQ Director Roger Klein's letter notified researchers that continuation funding for active grants would not be provided [2].HHS has characterized these as "non-awards" rather than terminations, a distinction the agency says reflects the director's statutory authority to determine whether continuation funding is in the federal government's best interest [3]. Grantees and advocacy groups dispute this, noting the practical effect is the same: ongoing, previously funded projects are ended mid-award-period [3][4]. Academy Health identified at least 45researchers and institutions that had received nearly identical letters as of roughly July 20 [3]. By July 22, STAT News and Academy Health's tracking put the confirmed total at a minimum of 78 grants worth a combined$200 million, including $109.2 million in previously committed but undisbursed funding that was withdrawn [2].
The money: appropriated but unspent
AHRQ was required to return $80 million of unused fiscal2025 funding, and its fiscal 2026 appropriation of $345 million already represented a 6.4% cut from the prior year before the current spending slowdown [5]. The agency has not issued a new grant in more than a year.
Leadership and the stated rationale
Roger Klein, a physician and attorney with a background in genomics and diagnostics, was appointed AHRQ director in mid-2025 [7].Two AHRQ officials told KFF Health News that Klein has said artificial intelligence can replace much of the evidence review and analytics work traditionally performed by AHRQ scientists [1]. That view is consistent with a July 22, 2026 report from White House science adviser Michael Kratsios, which called for federal science funding to refocus on individual scientists rather than "legacy institutions" and to build around AI rather than traditional peer review [1].
Pushback: litigation and congressional response
The Society of General Internal Medicine and the North American Primary Care Research Group have filed suit against HHS Secretary Robert F. Kennedy Jr. over the stoppage of research grants [6].This year's HHS funding law included new language, for the first time, requiring the department to "support staffing levels necessary to fulfill its statutory responsibilities," language read by observers as a direct response to the earlier reduction-in-force efforts at AHRQ [4].
Why This matters for sponsors, sites, and health systems
This development compounds a financial pressure pattern already documented in Sikara's 2026 clinical research trends outlook: research sites and health systems reliant on federal safety and quality infrastructure funding should treat AHRQ's near-total spending freeze as an active operational risk rather than a distant policy dispute. Organizations with active or pending AHRQ awards should confirm award status directly with program officers, document all correspondence regarding "non-award" notices for potential appeal, and avoid assuming that appropriated funding guarantees disbursement in the current environment.
References
\